Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Cytokinetics upgrade details — to Strong Buy at Needham; tgt raised to $22 (11.25)Needham upgrades CYTK to Strong Buy from Buy and raises their tgt to $22 from $17. The Phase III VITALITY-ALS study of tirasemtiv in amyotrophic lateral sclerosis (ALS) is expected to read out by year end. The Phase IIb study missed its primary endpoint, leading to low investor expectations of the outcome for Phase III. However, this well powered (n=711) trial hit on the pre-specified secondary endpoint of slow vital capacity (SVC) with high statistical significance (p=0.0006) and SVC is the primary endpoint in VITALITY. Cytokinetics owns US and European rights to tirasemtiv and intends to commercialize the drug on its own. <strong>Firm forecasts >$300M in 2022 US sales. Following a recent royalty financing, they est CYTK holds >$230M in pro forma cash, which they believe is more than adequate to launch tirasemtiv.</strong></td> </tr></table>"